Search

Search Constraints

You searched for: Author/Creator McCabe, Christopher

Search Results

1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019)

2. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019)

7. An MRI-Histological Study of White Matter in Stroke-Free SHRSP. Issue 5 (May 2013)

10. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. (October 2015)